Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan ...

Not only has Diovan's patent expired without any generic competition, but rivals for a combo drug, Diovan HCT, have already launched, because Ranbaxy's exclusivity doesn't apply. And Mylan should know ...

The U.S. Food and Drug Administration has approved a new generic of the blood pressure medication valsartan to help alleviate a recent shortage due to multiple safety recalls. Recalls have only ...

A few years ago India’s Alkem Laboratories was in the hot seat with the FDA, having had several plants cited by inspectors. Today it is in the driver’s seat after the agency approved its new generic ...

EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...

NEW YORK — Generic drug maker Sandoz has launched an authorized generic version of a drug used to treat hypertension. The generics division of Swiss drug maker Novartis announced the introduction of ...

WASHINGTON Diovan was recently approved for treating pediatric hypertension in 6 to 16 year old patients. The approval was a for a supplemental new drug application, approved by the Division of ...

Aug. 4, 2005 — The U.S. Food and Drug Administration (FDA) has approved valsartan to reduce cardiovascular mortality in patients with left ventricular dysfunction/failure following a myocardial ...

Approvals consistent with current US treatment guidelines to start appropriate patients on combination therapies[1] Up to 80% of patients may need multiple medications to help them reach blood ...